The molecular interplay between the phosphoinositide 3-kinase (PI3K) pathway and mammalian target of rapamycin (mTOR) signalling in the control of cell growth and proliferation has been the subject of much interest and debate amongst cell biologists. A recent escalation of research in this area has come from the discovery of the tuberous sclerosis complex gene products, tuberin and hamartin, as central regulators of mTOR activation. The PI3K effector Akt/protein kinase B has been found to directly phosphorylate tuberin and is thereby thought to activate mTOR through inhibition of the tuberin-hamartin complex. The many recent studies aimed at defining the molecular nature of this revamped PI3K/Akt/mTOR pathway are reviewed here. The collective data discussed have laid the groundwork for important new insights into the many cancers caused by aberrant PI3K activation and the clinically challenging tuberous sclerosis complex disease and have suggested a possible means of treatment for both.
Introduction
Class I phosphoinositide 3-kinases (PI3Ks) and the mammalian target of rapamycin [mTOR; also known as FKBP12 and rapamycin-associated protein (FRAP)] are critical regulators of cell proliferation and growth. PI3K is activated by most mitogenic stimuli, while mTOR requires activating inputs signalling the presence of both mitogens and sufficient nutrients. In response to these signals, PI3K and mTOR co-ordinately activate protein synthesis and subsequent cell growth through common downstream effectors. However, the nature of the molecular relationship between PI3K and mTOR has been difficult to elucidate and has been the subject of many studies and much debate within the signal-transduction field (reviewed in [1] ). Signalling
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events downstream of mTOR, such as activation of the 70 kDa ribosomal S6 kinase (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation, are sensitive to both an mTOR inhibitor (rapamycin) and PI3K inhibitors (wortmannin or LY294002) [2, 3] . The provocative question has been whether PI3K controls a pathway that is parallel to mTOR signalling and that converges on the same downstream effectors or whether PI3K controls these effectors through upstream regulation of mTOR. There are published data to support both of these models (e.g. [4] [5] [6] [7] ). As discussed in this review, the recent identification of the tuberous sclerosis complex (TSC)-2 gene product tuberin as a direct target of the PI3K-regulated Ser/Thr kinase Akt [also known as protein kinase B ('PKB')] has shed much light on this controversy.
Tuberin: a new target of the PI3K/Akt pathway
TSC is a disease that affects approx. 1 in 6000 individuals and is characterized by the occurrence of benign tumours, often classified as hamartomas, most commonly present in the brain, kidneys, lungs and skin (reviewed in [8] ). Although these tumours rarely become malignant, the clinical manifestations of TSC can be quite severe and include neurological disorders such as epilepsy, autism and mental retardation, as well as renal and pulmonary failure, and skin lesions. TSC is caused by mutations in one of two tumoursuppressor genes: TSC1, encoding hamartin, or TSC2, encoding tuberin. Hamartin and tuberin form a complex [9] , which genetic evidence suggests is essential for the function of the two proteins [10] [11] [12] [13] . However, until recently, how this complex controls cell growth and proliferation was unknown, and its molecular function remains undefined.
The first indications that the tuberin-hamartin complex might function within the PI3K pathway came from genetic studies in Drosophila [10, 12, 13] . Genetic epistasis analyses placed the Drosophila homologues of hamartin (dTSC1) and tuberin (dTSC2) in a pathway that antagonizes insulin signalling downstream of, or parallel to, the Drosophila PI3K/ Akt pathway. Interestingly, in humans, germline mutations in the gene encoding the phosphoinositide 3-phosphatase, phosphatase and tensin homologue deleted on chromosome 10 (PTEN), another tumour suppressor that antagonizes PI3K signalling, leads to syndromes with some phenotypic similarities to TSC (e.g. widespread hamartomas and neurological abnormalities; reviewed in [14] ). Together, these observations suggested the existence of a biochemical link between PI3K signalling and the tuberin-hamartin complex.
Our laboratory identified tuberin in a combined biochemical and bioinformatics screen for novel PI3K-dependent Akt substrates [15] . We found that tuberin was phosphorylated on Akt consensus phosphorylation motifs in a growth factor-(e.g. serum, platelet-derived growth factor, insulin and insulin-like growth factor 1) and PI3K-dependent manner, and that Akt is the in vivo tuberin kinase. We determined that Ser-939 and Thr-1462, the only two predicted Akt sites conserved in dTSC2, are the major PI3K-dependent phosphorylation sites on human tuberin. In an independent Drosophila study, the corresponding two sites on dTSC2 (Ser-924 and Thr-1518) were found to be phosphorylated by dAkt [16] . Additionally, using two-dimensional phosphopeptide mapping, another group identified the rat tuberin equilavent of human Ser-939 and Thr-1462 along with Ser-1130 or Ser-1132 as in vivo Akt phosphorylation sites on tuberin [17] . Based on these collective data and bioinformatics analysis [18] , it appears that Akt phosphorylates human tuberin on three positions (Ser-939, Ser-1130 and Thr-1462), thereby providing a direct biochemical link between PI3K signalling and the tuberin-hamartin complex.
Functional consequences of Akt-mediated tuberin phosphorylation
Although the molecular function of the tuberin-hamartin complex has yet to be determined, there is now considerable evidence demonstrating a role in regulation of S6K1, a downstream target of mTOR. In Drosophila, dS6K was found to be genetically epistatic to dTSC1 and dTSC2, and the genetic interaction suggests that the dTSC1-dTSC2 complex negatively regulates dS6K function in cell-size control [10, 13] . Additionally, TSC1
− / − mouse embryonic fibroblasts and TSC2 − / − rat smooth muscle and epithelial cells exhibit constitutive activation of S6K1 [19, 20] , further suggesting that the tuberin-hamartin complex somehow negatively regulates S6K1. Since the PI3K/Akt pathway had been implicated previously in S6K1 activation through an unknown mechanism (e.g. [21, 22] ), we hypothesized that the phosphorylation of tuberin by Akt might inhibit the function of the tuberin-hamartin complex and thereby relieve its inhibition of S6K1.
Our group [15] and Inoki and collaborators [17] independently found that expression of a tuberin allele with its Akt phosphorylation sites mutated to alanine could dominantly inhibit both the basal and growth factor-induced activation of S6K1. However, overexpression of wild-type tuberin alone had very little effect on S6K1 activity. Furthermore, expression of a non-phosphorylatable version of dTSC2 blocked the Akt-induced increase in ommatidia size within the Drosophila eye disc [16] . Together, these data demonstrate that tuberin phosphorylation by Akt inhibits the function of the tuberin-hamartin complex. However, the molecular mechanism of this inhibition is still unresolved.
Two groups have reported evidence that phosphorylation of tuberin by Akt might decrease the stability of the tuberin-hamartin complex [16, 17] , whereas our laboratory and others do not detect such an effect [15, 23] . Disruption of the tuberin-hamartin complex is an attractive mechanism of inhibition, as the proteins are believed to function solely as a complex. Acidic residue (i.e. phosphomimetic) substitutions of the Akt phosphorylation sites on tuberin were found to reduce the amount of tuberin that coimmunoprecipitates with hamartin [17] . In Drosophila S2 cells, complex formation between exogenously expressed tuberin and hamartin was significantly disrupted following just 20 min of insulin treatment, and this could be blocked by inhibition of PI3K or expression of a non-phosphorylatable tuberin [16] . However, in analogous experiments analysing association of exogenous tuberin with endogenous hamartin in mouse and human cells, we did not detect any correlation between growth factor-induced phosphorylation of tuberin and the amount of associated hamartin over a 12 h time course [15] . Furthermore, despite a greater than 20-fold increase in tuberin phosphorylation when co-expressed with Akt, no difference in the quantity of hamartin that coimmunoprecipitates with this tuberin was detected. We also find that tuberin specifically complexed with hamartin is phosphorylated on Akt sites in response to serum stimulation (B.D. Manning, unpublished work). Therefore, it seems unlikely that Akt-mediated phosphorylation of tuberin acutely disrupts the tuberin-hamartin complex in mammalian cells. The results with the phosphomimetic tuberin mutants [17] could be explained by a model in which phosphorylation of monomeric tuberin blocks its association with hamartin, whereas once in a complex with hamartin, tuberin phosphorylation has little effect on complex stability. Interestingly, pulse-chase experiments have demonstrated that increased phosphorylation of tuberin, by expression of constitutively active Akt or mimicked with acidic residue substitutions at Akt sites, correlates with a decrease in the protein stability of both tuberin and hamartin [17, 23] . This degradation appears to be through a ubiquitin/proteasomedependent pathway. Therefore, the Akt-mediated phosphorylation of tuberin within the tuberin-hamartin complex might ultimately lead to increased degradation of both proteins.
As with many other well-characterized Akt substrates [e.g. glycogen synthase kinase 3, forkhead in rhabdosarcoma L1 (FKHRL1), Bad] (reviewed in [24] ), phosphorylation of tuberin by Akt exerts an inhibitory effect on tuberin function. Akt-mediated phosphorylation inhibits FKHRL1 and Bad by creating binding sites for 14-3-3 proteins, which subsequently sequester these targets [25, 26] . Whereas none of the mapped in vivo Akt-phosphorylation sites (Ser-939, Ser-1130/1132, Thr-1462) on human tuberin strongly match predicted 14-3-3-binding sites [18] , several groups have addressed regulation of tuberin by 14-3-3 and the potential involvement of Akt in this regulation [27] [28] [29] [30] . These groups find that tuberin, within the tuberin-hamartin complex, can bind to all isoforms of 14-3-3 in a phophorylation-dependent manner. Two of these studies implicate Akt in mediating this association [27, 29] . However, two other studies found this association to be independent of the Akt-phosphorylation sites on tuberin [28, 30] . Together, these latter studies quite convincingly demonstrate that phosphorylation of Ser-1210 (Ser-1254 on full-length tuberin), rather than any of the Akt phosphorylation sites, is essential for 14-3-3 binding. Furthermore, the association of tuberin and 14-3-3 was not affected by pharmacological inhibition of the PI3K/Akt pathway [28] . Although the functional consequence of this association is still unclear, there is some indication that 14-3-3 binding to the tuberin-hamartin complex hinders its ability to inhibit S6K1 [28, 30] . The identity and mode of regulation, if any, of the Ser-1210/Ser-1254 kinase are currently unknown. However, the site weakly resembles a protein kinase D/protein kinase Cµ site [18, 31] . While some involvement of Akt in the 14-3-3-mediated control of the tuberinhamartin complex has not been ruled out, it appears that this mode of regulation occurs independently of the PI3K/Akttuberin pathway.
Other potential mechanisms of tuberin inhibition by Aktmediated phosphorylation have yet to be tested rigorously. This is mostly due to our lack of understanding of the molecular function of the tuberin-hamartin complex. Tuberin contains a region of homology to GTPase-activating proteins (GAPs) for the Rap family of small G-proteins and has been shown to have weak in vitro GAP activity towards both Rap1 [32] and Rab5 [33] . Although it is currently unclear whether tuberin is a physiological GAP for any small G-protein, it would be interesting to know if Akt phosphorylation of tuberin affects its GAP activity. It would also be of interest to know whether phosphorylation of tuberin by Akt alters its subcellular localization. The majority of tuberin and hamartin has been localized biochemically to cytosolic fractions, with a much smaller amount found in membrane fractions of the Golgi and early endosomes or bound to cytoskeletal components [34] . Using time-lapse video microscopy our laboratory has failed to detect any difference in localization of green fluorescent protein fusions of wild-type tuberin or Akt-phosphorylation-site mutants of tuberin in response to PI3K activation or inhibition (B.D. Manning, unpublished work). Green fluorescent protein-tuberin exhibited a diffuse cytoplasmic localization under all conditions, and immunofluorescence with a phospho-specific antibody to Thr-1462 of tuberin displayed the same pattern for endogenous tuberin under conditions in which the PI3K/Akt pathway is active. Therefore, there is not a dramatic change in localization of the tuberin-hamartin complex upon phosphorylation of tuberin, although a more subtle change cannot be ruled out at this time. Clearly, more studies must be conducted to define the molecular nature of Akt's inhibition of the tuberin-hamartin complex.
Control of mTOR by the tuberin-hamartin complex
While still somewhat controversial, it now appears that the tuberin-hamartin complex inhibits S6K1 through upstream inhibition of mTOR signalling. Cells with a loss of tuberin or hamartin, through mouse knockouts or the use of small interfering RNA (siRNA), exhibit constitutive phosphorylation of two distinct downstream mTOR targets, S6K1 and 4E-BP1 [17, 19, 35] . Furthermore, the constitutive phosphorylation of these proteins requires mTOR function. Reciprocally, overexpression of tuberin and hamartin together, but neither alone, blocks both S6K1 phosphorylation/activation and 4E-BP1 phosphorylation/inhibition [17, 35, 36] . To further address whether the tuberin-hamartin complex acts through inhibition of mTOR, three different groups used rapamycinresistant mutants of S6K1 (i.e. S6K1 alleles that are activated in an mTOR-independent manner). Two groups found that, unlike wild-type S6K1, rapamycin-resistant S6K1 mutants were also resistant to inhibition by overexpression of the tuberin-hamartin complex, suggesting that this complex acts through mTOR [17, 36] . However, a third group concluded the opposite when they found a rapamycin-resistant mutant was still inhibited by the tuberin-hamartin complex [35] . This discrepancy can likely be explained by the fact that different rapamycin-resistant S6K1 alleles were used in these studies. One question is whether or not the S6K1 mutant used by Jaeschke et al. [35] is fully resistant to rapamycin (i.e. fully independent of mTOR). While their controls suggest that it is [35] , other studies have found that similar S6K1 truncation mutants, although without glutathione S-transferase fused to their N-termini, are only partially resistant to rapamycin [37, 38] . Another possible cause for this discrepancy is the nature of the S6K1 kinase assays performed. The two groups concluding mTOR dependence for the tuberinhamartin complex used recombinant ribosomal S6 protein 
Signalling pathways leading to inhibition of the tuberin-hamartin complex are colour-coded with the amino-acid residues on tuberin that they modify (numbering is for full-length human tuberin). In response to mitogens, PI3K activates Akt, which inhibits tuberin by phosphorylating Ser-939, Ser-1130 and Thr-1462 (red). Another putative signal activates an unknown kinase that phosphorylates Ser-1254 on tuberin, thereby creating a binding site for 14-3-3 proteins, which appears to inhibit the complex (blue). The availability of nutrients (e.g. amino acids) might also lead to inhibition of the tuberin-hamartin complex through an, as yet, unknown mechanism (orange). These signals would activate mTOR by relieving its inhibition by the tuberin-hamartin complex. mTOR activation leads to activation of S6K1 and inhibition of 4E-BP1, two important events in the initiation of protein synthesis. Aside from the tuberin-hamartin complex, there exist parallel pathways that are both PI3K-dependent [e.g. through phosphoinositide-dependent kinase 1 (PDK1), PKCζ , Cdc42 and/or Rac] and -independent (not shown) that signal to components downstream of mTOR.
as a substrate [17, 36] , whereas Jaeschke et al. used histone H2B [35] . The reason behind the different outcomes of this important set of experiments awaits further resolution.
An abundance of other evidence further suggests that the tuberin-hamartin complex acts at the level of mTOR inhibition. In Drosophila, genetic epistasis analyses place dTSC1 and dTSC2 as upstream inhibitors of dTOR [39] . In mammalian cells, reduction of tuberin levels by siRNA increases phosphorylation of Ser-2448 on mTOR [17] , a modification that correlates with mTOR activity [40] [41] [42] , while overexpression of the tuberin-hamartin complex blocks phosphorylation of Ser-2448 and inhibits mTOR kinase activity [17] . Furthermore, endogenous dTSC2 was found to co-immunoprecipitate with exogenously expressed dTOR [39] , suggesting the possibility of a fairly direct mechanism of TOR regulation by the tuberin-hamartin complex. Interestingly, the tuberin-hamartin complex can also block PI3K-independent inputs into mTOR activation. mTOR activity is sensitive to the availability of nutrients, and upon withdrawal of amino acids mTOR signalling is shut down. Several groups have found that mTOR activation upon re-addition of amino acids to the growth media of mammalian or Drosophila cells could be blocked by overexpression of tuberin and hamartin [17, 36, 39] , and reduction of tuberin levels by siRNA led to constitutive mTOR signalling in the absence of amino acids [39] . Taken together, the data discussed here suggest a model in which many, if not all, signals leading to mTOR activation must act, at least in part, through inhibition of the tuberin-hamartin complex (Figure 1 ). While mitogens signal to the complex through Akt activation, it will be very interesting to know how amino acid availability exerts its inhibition on the complex.
A rebirth for the PI3K/Akt/mTOR pathway?
The positioning of PI3K, Akt, mTOR and downstream targets of mTOR (e.g. S6K1 and 4E-BP1) within the same or parallel signalling pathways has been the subject of much controversy. The discovery of the tuberin-hamartin complex as a regulatory link between Akt and mTOR provides evidence that these proteins are in the same pathway downstream of mitogenic stimuli. The components of this pathway are well conserved in Drosophila [10, 12, 13] , and current studies suggest that they function in a similar manner to their mammalian counterparts [16, 39] . However, some recent studies in Drosophila have demonstrated dPI3K-independent inputs into dS6K: dS6K does not require dPI3K or dPKB/Akt for its activation [6] and loss of dPTEN leads to increased activation of dPKB/Akt but not dS6K [43] . These studies have been used to argue that PI3K and mTOR are on distinct and parallel signalling pathways. In actuality, they just further demonstrate that there are multiple pathways, aside from mitogen-stimulated PI3K, leading to activation of mTOR signalling, as has been well demonstrated in mammalian cells (reviewed in [1, 44] ). Furthermore, in mammalian cells S6K1 activation is sensitive to PI3K activity [2] and is enhanced, along with 4E-BP1 phosphorylation, upon loss of PTEN [7, 45] . The fact that these signalling proteins do not have clear-cut linear relationships to one another underscores the fact that many parallel pathways diverge from the lipid products of PI3K and from Akt and that signals from both mitogens and nutrients regulate mTOR. The cumulative data on mitogenic signalling by these proteins suggest the existence of a linear pathway of PI3K and Akt controlling mTOR through phosphorylation and inhibition of the tuberin-hamartin complex, while other parallel PI3K-dependent and -independent [e.g. extracellular-signal-regulated kinase (ERK)] [46] pathways converge on effectors downstream of mTOR ( Figure 1) .
Much work remains to more clearly define the synergistic relationship between these signalling molecules within mouse models and in human disease. Interestingly, tumours and tumour-derived cell lines in which the PI3K pathway is aberrantly activated, most commonly through loss of PTEN, display an enhanced sensitivity to rapamycin and rapamycin analogues [5, 7, 45, 47] . This implies that activation of mTOR through Akt-mediated phosphorylation of tuberin is critical for the oncogenic properties of the PI3K pathway. Additionally, the proliferation of TSC2 −/− mouse cells and tumour growth within the Eker rat model of TSC are sensitive to rapamycin [35, 48, 49] . Therefore, rapamycin and its analogues might be potent drugs in the treatment of both the TSC disease and the many cancers caused by uncontrolled signalling through the PI3K pathway.
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